about
Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidenceNonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid responseDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyLiraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialLow energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronismPathogenesis of non-alcoholic fatty liver disease.11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excessRegulation of lipogenesis by glucocorticoids and insulin in human adipose tissue.A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency.Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis.Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice.Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiencyIncreased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosisDifferential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis."Cushing's disease of the omentum"--fact or fiction?Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue.5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.SFRP2 Is Associated with Increased Adiposity and VEGF Expression.Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in ManGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis.Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.Lack of hexose-6-phosphate dehydrogenase impairs lipid mobilization from mouse adipose tissueImpaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.Modulation of glucocorticoid action and the treatment of type-2 diabetes.Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?Non-alcoholic fatty liver disease and diabetes.Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake.11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.Mortality in patients with pituitary disease.
P50
Q22242080-D6FF872E-505A-4529-B2BD-66AC723C4FB8Q24631570-017194EA-4362-456A-9ED0-16C1ED572B73Q28286308-C5AD05DD-88BB-469B-AE94-2AC0AE305529Q28543075-6C3098CA-C26C-4A59-B566-890D81DA98B9Q28661700-36819063-25E6-48EC-BC29-31F1A3CD0E5DQ28750454-EB8065CD-6451-431B-A774-CE607CA569C8Q30392597-28D51EA9-7998-4C27-A6CD-52B2158113A3Q30577903-6DC9D290-B71C-484B-84EB-181541CE4AC8Q33579003-6C6A2099-9A16-4CE9-9F05-00FB5C33F6EFQ33606303-343765F7-6CA5-4FA6-8CE3-2062C8BB51F4Q33789944-A867633D-BE12-4866-A6E7-8E140754FA6DQ34056185-C7E6965F-6545-41CB-B117-734F23455AACQ34169832-82DF51F4-0FCC-452B-8619-4F5A0B472FE5Q34213892-869B4E39-DDB6-4A68-9D78-C21226A64ED6Q34310464-E1077C46-3617-4DA6-9895-0E78E5C6B384Q34316501-FC148B9A-C2B9-4924-8089-F87B02ECA9D8Q34796382-F3CE2C57-4F57-44CD-9748-851D5B01506CQ34989929-B29DCFE9-91CC-40BA-9178-ECECBDA446FAQ35056710-B5B213B6-8EA3-451B-9718-E58A3D741E0CQ35604590-0C4030BD-F712-4436-92E9-19E3304DDE5DQ35765858-7E046ED5-9EEF-48C9-BAB6-F5973FAE84C0Q35825622-A5B0C7B9-FE3E-48A9-910B-87BF3CC8F519Q35878846-2363F11F-CC96-4079-B4CA-6EDB35F34C4AQ36118229-4E93E429-6114-4279-AA15-8376CBD6A483Q36148529-21480456-BB93-4EDF-8D79-DA26876AEDFAQ36331122-173B6034-F2ED-418B-B3DD-545D5E1E2216Q36431676-39D514D6-154C-402F-8509-4706228776A5Q36465496-5B7D7AE8-9A8A-48E0-A007-688FEA9249A2Q36562971-CDE9B8B7-F05F-4198-A6C3-8A54A809BD8EQ36575445-E481F2DF-F692-4675-9662-D706E4C5D0D3Q36578866-B7B70830-F651-49C8-A2AA-CF2C06DF05A8Q36906339-8231BA5B-191C-4164-9573-7147B4820DB7Q37022376-A1766C5D-B278-44C0-BA95-59008D3777C0Q37023017-F730952C-FBEE-4C33-80DB-9F83D5855A04Q37091659-35C78EC2-035A-4E1E-8C8E-8D71EF135BB6Q37341944-FE9AFBB7-D53C-402B-855F-AFA5E5D83303Q37400786-86766E1C-3175-4021-8299-5787BA36B2DFQ37406308-A8D90282-32D9-4562-A7FD-7CB360C829B4Q37639062-ECA0AD8A-2560-4AA5-A86B-2001F9ACCE43Q37677961-71B66BE5-1C54-4D17-86BF-E5A2C005522A
P50
description
researcher ORCID ID = 0000-0002-3170-8533
@en
wetenschapper
@nl
name
Jeremy W Tomlinson
@ast
Jeremy W Tomlinson
@en
Jeremy W Tomlinson
@nl
type
label
Jeremy W Tomlinson
@ast
Jeremy W Tomlinson
@en
Jeremy W Tomlinson
@nl
altLabel
Jeremy Tomlinson
@en
prefLabel
Jeremy W Tomlinson
@ast
Jeremy W Tomlinson
@en
Jeremy W Tomlinson
@nl
P106
P21
P31
P496
0000-0002-3170-8533